delns1-2019-ncov-rbd-opt1
Trade name: Pneucolin
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Feb 8, 2022 (NCT05200741)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05855408 | Phase 4 | May 18, 2023 | Government of China |
| NCT05200741 | Phase 2 | Feb 8, 2022 | The University of Hong Kong |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 1 | 1 | 2023 |
| The University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1